[go: up one dir, main page]

Kensler et al., 1982 - Google Patents

Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis

Kensler et al., 1982

Document ID
7516554380013497642
Author
Kensler T
Jayaram H
Cooney D
Publication year
Publication venue
Advances in Enzyme Regulation

External Links

Snippet

The inhibitory activities of two oncolytic amino acid analogs, acivicin and n-(phosphonacetyl)- l-aspartate, on pyrimidine biosynthesis have been examined in a murine tumor line, the Lewis lung carcinoma. Acivicin, an antimetabolite elaborated by Streptomyces sviceus …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Similar Documents

Publication Publication Date Title
Brockman et al. Inhibition of ribonucleotide reductase, DNA synthesis, and L1210 leukemia by guanazole
US11826316B2 (en) Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
Heidelberger Fluorinated pyrimidines and their nucleosides
Cory et al. Inhibitors of ribonucleotide reductase: Comparative effects of amino-and hydroxy-substituted pyridine-2-carboxaldehydethiosemicarbazones
Shirasaka et al. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats
Laliberte et al. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase
Johnson et al. The clinical impact of screening and other experimental tumor studies
Peters et al. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)
KR100352046B1 (en) Pharmaceutical combination preparations for strengthening temozolomide in human tumor cells
Hall et al. The cytotoxicity of N-pyridinyl and N-quinolinyl substituted derivatives of phthalimide and succinimide
KR20230020565A (en) Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors
Jost et al. Regulation of the synthesis of rat liver serine dehydratase by adenosine 3′, 5′-cyclic monophosphate
Kensler et al. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis
Cooper et al. Irreversible inhibition of dehalogenation of 5-iodouracil by 5-diazouracil and reversible inhibition by 5-cyanouracil
Workman et al. CB 1954 revisited: II. Toxicity and antitumour activity
Markovits et al. Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II β isoform
Elliott et al. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice
Zembower et al. Enantiospecific syntheses of. alpha.-(fluoromethyl) tryptophan analogs: interactions with tryptophan hydroxylase and aromatic L-amino acid decarboxylase
O’Dwyer et al. Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs
Kensler et al. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma
EP0205586B1 (en) Composition comprising udpg and other anti-tumor drugs for treatment of tumors
Takechi et al. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts
Baumann et al. Reductive activation of the prodrug 1, 2-bis (methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl) ethoxy] carbonyl] hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O6-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance
Tarnowski et al. Combination therapy of animal tumors with L-asparaginase and antagonists of glutamine or glutamic acid
Hall et al. The effects of boron containing peptides on L1210 lymphoid leukemia metabolism